Tofacitinib Receives New Boxed Safety Warning

A new boxed warning has been added to the labeling of tofacitinib (Xeljanz, Xeljanz XR) based on preliminary safety data from an ongoing postmarketing trial showing an increased risk of thrombosis and death in patients with at least one cardiovascular risk factor who were taking the 10-mg twice-daily dose.Tofacitinib 10 mg twice daily is approved as induction treatment for ulcerative colitis; the dose is not approved to treat rheumatoid arthritis or psoriatic arthritis.NPs should adhere to the dosing regimens listed on tofacitinib's labeling. Patients should be assessed for thrombosis and taught to seek emergency help if they develop signs or symptoms of this condition.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research